Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (400)

Latest Posts

About This Stock More About This Stock
Large Cap Biopharmaceutical Valuations: Q1 2017
Article By: Rod Raynovich
Monday, May 8, 2017 8:45 PM EDT
Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics.
In this article: BMY, RHHBY, FBIOX, ALXN, IBB, REGN, AMGN, BIIB, CELG, GILD, FBT, XBI, ABBV
Read
Biotech Bonanza – Approaching An Inflection Point
Article By: Tarun Chandra, CFA
Saturday, May 6, 2017 6:42 PM EDT
Biotechs are performing well this year even in an uncertain environment. Policy clarity is important and we may be approaching an inflection point for them to push higher. Investors should maintain exposure to this volatile but promising sector.
In this article: IBB, SPY, XBI, ALXN, AMGN, BIIB, CELG, BIVV, LLY, MRK, PFE, INCY, GILD, SRPT
Read
A Bronze Bear Defers To A Raven’s Caw
Article By: Michele Schneider
Wednesday, May 3, 2017 8:16 PM EDT
Today, the Fed released their minutes. They announced that the benchmark interest rate will stay unchanged. With the first quarter GDP at .7%, no wonder. The Fed went on to say that they saw the slowing growth as “likely to be transitory.”
In this article: GREK, IBB, GILD, GLD, IWM, IYT, KRE, SMH, XRT Also: QQQ, DIA, IYR, SLV, SPY, TAN, TLT, USO, UUP
Read
Gilead Misses Q1 Earnings And Revenue Estimates, Stock Drops
Article By: Zacks Investment Research
Tuesday, May 2, 2017 8:50 PM EDT
Gilead Sciences released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion.
In this article: GILD
Read
Gilead Sciences Reports Worse-Than-Expected Q1 Earnings; Revenues Plunge 16.5% Y-O-Y
Article By: Lorimer Wilson
Tuesday, May 2, 2017 5:25 PM EDT
Gilead Sciences, Inc. posted worse than expected first quarter earnings and revenue results, as sales of its HCV focused drugs plummeted 40% from last year.
In this article: GILD
Read

PARTNER HEADLINES

Latest Tweets for $GILD

No tweets yet!

$GILD

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kurt Benson 3/24/2017 10:12:59 PM

I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.

www.talkmarkets.com/.../interview-with-vitality-biopharma-inc

Not a lot of info on the company though.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kirk Sheffield 3/24/2017 10:11:55 PM

I think $GILD will rebound. This isn't the only product they have in their pipeline.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Alpha Stockman 3/24/2017 10:07:45 PM

I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.

Gilead Sciences Receives Canadian Approval For HIV Drug
David Reynolds 2/20/2017 10:04:11 PM

The opening up of this market for #GileadSciences should bode well for the stock $GILD.

Gilead Sciences: Cheap Growth Or Value Trap?
Karen Klein 9/13/2016 5:39:48 PM

Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD

3 Cult Stocks To Avoid In 2015
Bruce Powers 1/26/2015 8:01:06 AM

Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 6:09:51 PM

Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 4:48:08 PM

I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.

1 to 8 of 8 comments